RESUMO
INTRODUCTION: This article provides a global overview of patent deposits for broadly neutralizing antibodies (bNAbs), which have emerged as a key strategy for HIV cure and future HIV vaccines. Scientific and technological barriers to the discovery of an effective HIV vaccine in the last 40 years have raised concerns on the potential for relevant advances in this area. Nevertheless, recent breakthrough studies have identified novel immune pathways for new innovative HIV vaccine and HIV cure strategies. AREAS COVERED: In our patent study, we have identified in a global scale, in the last decade, a sharp increase in the number of bNAbs' patent deposits related to HIV prevention and treatment strategies, reaching 90 bNAbs in 2017, protected by 184 different patent deposits. Refining our patent search to the different stages of bNAbs' development has also allowed us to identify 12 of them already at clinical stage of research (VRC01, 10E8, 3BNC117, 10-1074, 2G12, 2F5, KD-247, 4E10, PG9, PGDM1400, PGT121, and VRC07). We describe these recent breakthroughs and discuss the prospects and limitations of these novel strategies. EXPERT OPINION: Our results indicate the intellectual property outcomes of a scientific revolution in this field, expressing innovative modifications in antibodies to increase their potency and half-life, which have resulted in extremely potent antibodies that could provide novel preventive and therapeutic HIV strategies.
Assuntos
Vacinas contra a AIDS/imunologia , Anticorpos Neutralizantes/imunologia , Infecções por HIV/imunologia , Animais , Infecções por HIV/prevenção & controle , Infecções por HIV/terapia , Humanos , Propriedade Intelectual , Patentes como AssuntoRESUMO
INTRODUCTION: Arterial hypertension affects over one billion people around the world, making the prevention and treatment of this disease vital. Despite the efforts made to develop new antihypertensive drugs, few new therapies have become available. Angiotensin-converting enzyme (ACE) inhibitors have heralded major steps forward in the treatment of arterial hypertension and cardiovascular diseases since the first compound of this class, captopril, was approved for clinical use in 1981. Areas covered: In this review, the authors investigated the patent documents that cite the priority patent for captopril, Squibb's first blockbuster, or any other patent from its patent family. The documents were classified into the following: new compounds, new compositions, treatment, process (preparation of a compound), use of a compound, and process for the preparation of an intermediate. Therefore, the readers can identify potential innovations in the field. Expert opinion: The pharmaceutical sector has attempted to provide significant technological developments on anti-hypertensive drugs based on the patenting of captopril, including the development of new compositions further comprising an ACE inhibitor and other antihypertensive agent, along with dual action compounds, novel molecules with dual activity. The target is to find a new agent with better blood pressure-lowering efficacy, improved safety and good tolerability proï¬le.
Assuntos
Anti-Hipertensivos/farmacologia , Captopril/farmacologia , Hipertensão/tratamento farmacológico , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/fisiopatologia , Desenho de Fármacos , Indústria Farmacêutica , Humanos , Hipertensão/fisiopatologia , Patentes como AssuntoRESUMO
Recently, research in the field of cancer nanotechnology has made notable progress, and, with the fast development of nanomaterials, new treatment strategies using nanoparticles are being explored that have the potential to overcome existing problems. The present review focuses on patenting as a key indicator of trends in nanoparticles with applications in the treatment of cancer. The impact of cancer on health and the use of nanoparticles are briefly described. Next, a survey of patents filed in the last 14 years is presented, the patents granted in the last four years are identified, and the focus areas of the main applicants are analyzed. The mix of targets identified for patented nanoparticles systems suggests that polymers and proteins are the main focus of the innovative efforts in this field.